This might explain why ALK targeted inhibitors have shown impressive clinical efficacy in ALK-rearranged malignancies, whereas in cancer patients expressing full-length ALK kinase clinical response remains unsatisfactory [38,74,75,76]. Here, ALK is linked to cancer.